The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...

Discover key earnings insights from Supernus Pharmaceuticals Q1 2025 call, highlighting 26% core product growth, ONAPGO launch, and robust strategic focus.

Supernus Pharmaceuticals Inc (SUPN) reports robust Qelbree sales and strategic advancements, despite facing increased losses ...

Early in the second quarter, we launched ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...

Supernus Pharmaceuticals, Inc. First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCO ...

"In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson's disease who are experiencing motor ...

First quarter adjusted operating earnings (non-GAAP) (1) increased 16% to $25.9 million. ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year ...

“In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson’s disease who are ...